A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407
Luis Paz‐Ares(Hospital Universitario 12 De Octubre), David Vicente(Hospital Universitario Virgen Macarena), Ali Tafreshi(Wollongong Hospital), Andrew Robinson(Kingston General Hospital), Héctor Soto Parrà(Azienda Ospedaliero-Universitaria Policlinico - Vittorio Emanuele), Julien Mazières(Hôpital Larrey), Bárbara Hermes(Universitätsklinikum Tübingen), İrfan Çiçin(Trakya University), Balazs Medgyasszay, Jerónimo Rafael Rodríguez‐Cid(Hospital Médica Sur), Isamu Okamoto(Kyushu University Hospital), Sung-Sook Lee(Inje University), Rodryg Ramlau(Poznan University of Medical Sciences), Vladimir Vladimirov(Pyatigorsk Oncology Center), Ying Cheng(Jilin Province Tumor Hospital), Xuan Deng(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ying Zhang(Statistics Belgium), Tuba Öcek Baş(Merck & Co., Inc., Rahway, NJ, USA (United States)), Bilal Piperdi(Merck & Co., Inc., Rahway, NJ, USA (United States)), Balázs Halmos(Albert Einstein College of Medicine)
Cited by 642Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis